Objective: To investigate the safety and efficacy of novel CD19-KIRS2/Dap12-BB chimeric antigen receptor T cells (CAR-T cells) in the treatment of relapsed/refractory B-cell malignancy (R/R BCM).
Methods: Three patients with R/R BCM treated with novel CD19-KIRS2/Dap12-BB CAR-T cells from June 2020 to November 2020 were enrolled, including 1 case of B-cell acute lymphoblastic leukaemia (B-ALL) and 2 cases of non-Hodgkin's lymphoma (NHL), and the efficacy and adverse reactions were observed.
Results: After CAR-T cells infusion, patient with B-ALL achieved complete remission (CR) and minimal residual disease (MRD) turned negative, and 2 patients with NHL achieved partial remission (PR). Grade 2 cytokine release syndrome (CRS) occurred in B-ALL patient, grade 1 CRS occurred in 2 NHL patients, and grade II to IV hematologic adverse reactions occurred in 3 patients, all of which were controllable and reversible. The progression-free survival (PFS) of the 3 patients was 143, 199, and 91 days, and overall survival (OS) was 282, 430, and 338 days, respectively.
Conclusion: The novel CD19-KIRS2/Dap12-BB CAR-T cells in treatment of 3 patients with R/R BCM have significant short-term efficacy and controllable adverse reactions, but the long-term efficacy needs to be further improved.
题目: 新型CD19-KIRS2/Dap12-BB CAR-T治疗复发难治B细胞肿瘤3例.
目的: 探讨新型CD19-KIRS2/Dap12-BB嵌合抗原受体T细胞（CAR-T）治疗复发/难治性B细胞肿瘤的安全性及有效性。.
方法: 以2020年6至11月采用新型CD19-KIRS2/Dap12-BB CAR-T治疗的3例复发/难治性B细胞肿瘤患者为研究对象，包括急性B淋巴细胞白血病1例，非霍奇金淋巴瘤2例，观察疗效及不良反应。.
结果: 急性B淋巴细胞白血病患者取得完全缓解和微小残留病灶转阴，2例非霍奇金淋巴瘤患者取得部分缓解。急性B淋巴细胞白血病患者发生2级细胞因子释放综合征，2例非霍奇金淋巴瘤患者发生1级细胞因子释放综合征，3例患者均发生Ⅱ-Ⅳ级血液学不良反应，上述不良反应均可控且可逆。3例患者无进展生存期分别为143、199、91 d，总生存期分别为282、430、338 d。.
结论: 新型CD19-KIRS2/Dap12-BB CAR-T治疗3例复发/难治性B细胞肿瘤患者近期疗效显著，且不良反应可控，而远期疗效有待进一步提高。.
Keywords: chimeric antigen receptor T cells; B-cell malignancy; KIRS2/Dap12.